Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability

Sherratt, Samuel; Dawoud, Hazem; Bhatt, Deepak L.; Maliński, Tadeusz; Mason, R. Preston

doi:10.1016/j.plefa.2021.102337

Cited by 38 publications

(23 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is known that EPA and docosahexaenoic acid have very different tissue distribution and disparate effects on membrane stabilization and fluidity, formation of cholesterol rafts and crystals, rates of lipid oxidation in lipoproteins and cells, inflammatory modulation, transcriptional regulation, and endothelial function. 47 , 48 , 49 , 50 , 51 …”

Section: Discussionmentioning

confidence: 99%

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Peterson

Bhatt

Steg

et al. 2022

JAHA

Self Cite

View full text Add to dashboard Cite

Background Patients who undergo percutaneous coronary intervention (PCI) are at increased risk for recurrent cardiovascular events despite aggressive medical therapy. Methods and Results This post hoc analysis focused on the subset of patients with prior PCI enrolled in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), a multicenter, randomized, double‐blind, placebo‐controlled trial of icosapent ethyl versus placebo. Icosapent ethyl was added to statins in patients with low‐density lipoprotein cholesterol <100 mg/dL and fasting triglycerides 135–499 mg/dL. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization. There were 8179 patients randomized in REDUCE‐IT followed for a median of 4.9 years, and 3408 (41.7%) of them had a prior PCI with a median follow‐up of 4.8 years. These patients were randomized a median of 2.9 years (11 days to 30.7 years) after PCI. Among patients treated with icosapent ethyl versus placebo, there was a 34% reduction in the primary composite end point (hazard ratio [HR], 0.66; 95% CI, 0.58–0.76; P <0.001; number needed to treat 4.8 years =12) and a 34% reduction in the key secondary composite end point of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR, 0.66; 95% CI, 0.56–0.79; P <0.001; NNT 4.8 years =19) versus placebo. Similarly, large reductions occurred in total coronary revascularizations and revascularization subtypes. There was also a 39% reduction in total events (rate ratio, 0.61; 95% CI, 0.52–0.72; P <0.001). Conclusions Among patients treated with statins with elevated triglycerides and a history of prior PCI, icosapent ethyl substantially reduced the risk of recurrent events during an average of ~5 years of follow‐up with a number needed to treat of only 12. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01492361.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Peterson

Bhatt

Steg

et al. 2022

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…Early studies in patients treated with EPA demonstrated reduced plaque volume, decreased inflammation, increased nitric oxide release, and higher rates of membrane stabilization. [7][8][9][10][11][12][13][14][15] In light of these positive findings, the Reduction of Cardiovascular Events with Icosapent Ethyl (IPE) -Intervention Trial (REDUCE-IT) was designed to explore, in a randomized fashion, the role of IPE in reducing adverse cardiovascular events and whether it too could mitigate ischemic risk to the degree IPE had done in JELIS. 16 The results of the trial were overwhelmingly positive, and since the original publication of the trial, there have been a myriad of subsequent analyses confirming the benefit of IPE in various patient groups.…”

Section: Introductionmentioning

confidence: 99%

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Bhatt¹,

Mason²,

Miller³

et al. 2022

Journal of Clinical Lipidology

Self Cite

View full text Add to dashboard Cite

“…However, the regulation of vascular tone is not the only function of NO. It is also involved in the regulation of platelet and leukocyte adhesion, thrombosis, and fibrinolysis [ 89 , 90 , 91 ].…”

Section: Cross-links In the Regulation Of Hemodynamics And Innate Imm...mentioning

confidence: 99%

Immune Function of Endothelial Cells: Evolutionary Aspects, Molecular Biology and Role in Atherogenesis

Kotlyarov

2022

IJMS

View full text Add to dashboard Cite

Atherosclerosis is one of the key problems of modern medicine, which is due to the high prevalence of atherosclerotic cardiovascular diseases and their significant share in the structure of morbidity and mortality in many countries. Atherogenesis is a complex chain of events that proceeds over many years in the vascular wall with the participation of various cells. Endothelial cells are key participants in vascular function. They demonstrate involvement in the regulation of vascular hemodynamics, metabolism, and innate immunity, which act as leading links in the pathogenesis of atherosclerosis. These endothelial functions have close connections and deep evolutionary roots, a better understanding of which will improve the prospects of early diagnosis and effective treatment.

show abstract

Omega-3 and omega-6 fatty acids have distinct effects on endothelial fatty acid content and nitric oxide bioavailability

Cited by 38 publications

References 63 publications

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Immune Function of Endothelial Cells: Evolutionary Aspects, Molecular Biology and Role in Atherogenesis

Contact Info

Product

Resources

About